| Overview |
| bs-4895R-FITC |
| PIRH2 Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse |
| Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PIRH2 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 25898 |
| Q96PM5 |
| Cytoplasm, Nucleus |
| ZCHY; ARNIP; CHIMP; PIRH2; RNF199; ZNF363; PRO1996; RING finger and CHY zinc finger domain-containing protein 1; Androgen receptor N-terminal-interacting protein; CH-rich-interacting match with PLAG1; E3 ubiquitin-protein ligase Pirh2; RING finger protein 199; Zinc finger protein 363; p53-induced RING-H2 protein; hPirh2; RCHY1 |
| Mediates E3-dependent ubiquitination and proteasomal degradation of target proteins, including p53/TP53, P73, HDAC1 and CDKN1B. Preferentially acts on tetrameric p53/TP53. Monoubiquitinates the translesion DNA polymerase POLH. Contributes to the regulation of the cell cycle progression. Increases AR transcription factor activity. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz